TDGF 1 is a novel predictive marker for metachronous metastasis of colorectal cancer

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• International Journal of Oncology

  2017cited by this paper
• Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines

  2009cited by this paper
• The epithelial-mesenchymal transition generates cells with properties of stem cells.

  2008cited by this paper
• Systemic treatment of colorectal cancer.

  2008cited by this paper
• Positive association of up‐regulated Cripto‐1 and down‐regulated E‐cadherin with tumour progression and poor prognosis in gastric cancer

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.

  2008cited by this paper
• Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte–macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus

  2007cited by this paper
• The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer.

  2007cited by this paper
• Cause and place of death in patients dying with colorectal cancer

  2007cited by this paper
• An update and our experience with metastatic liver disease.

  2007cited by this paper
• Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.

  2007cited by this paper
• Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group.

  2007cited by this paper
• Role of human cripto-1 in tumor angiogenesis.

  2005cited by this paper
• Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma

  2005cited by this paper
• Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

  2004cited by this paper
• A comparison of laparoscopically assisted and open colectomy for colon cancer.

  2004cited by this paper
• Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis.

  2004cited by this paper
• Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV‐Cripto‐1 transgenic mice

  2004cited by this paper
• Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

  2002cited by this paper
• Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.

  2002cited by this paper
• Leaving the neighborhood: molecular mechanisms involved during epithelial‐mesenchymal transition

  2001cited by this paper
• Induction and regulation of epithelial-mesenchymal transitions.

  2000cited by this paper
• Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas.

  2000cited by this paper
• Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells.

  2000cited by this paper
• Cripto: a novel epidermal growth factor (EGF)‐related peptide in mammary gland development and neoplasia

  1999cited by this paper
• Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells.

  1999cited by this paper
• Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

  1998cited by this paper
• Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.

  1994cited by this paper
• Cripto, a member of the epidermal growth factor family, is over‐expressed in human pancreatic cancer and chronic pancreatitis

  1994cited by this paper
• Expression of cripto in Human Pancreatic Tumors

  1994cited by this paper
• Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors.

  1992cited by this paper
• The E-cadherin promoter: functional analysis of a G.C-rich region and an epithelial cell-specific palindromic regulatory element.

  1991cited by this paper
• Differential expression of epidermal growth factor-related proteins in human colorectal tumors.

  1991cited by this paper
• Characteristics of invasive and noninvasive human colorectal adenocarcinoma cells.

  1990cited by this paper
• The American Joint Committee on Cancer.

  1984cited by this paper

• Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal

  2021cites this paper
• EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas.

  2012cites this paper
• Cripto-1: an embryonic gene that promotes tumorigenesis.

  2010cites this paper